AbbVie Non-GAAP EPS of $3.82 beats by $0.05, revenue of $17.4B beats by $50M, raises FY guid

AbbVie (ABBV) reported Q3 Non-GAAP EPS of $3.82, exceeding estimates by $0.05, with revenue of $17.4B, a $50M beat. Immunology portfolio revenue grew 16.3% to $9.165B. The company raised its full-year guidance.

Original reporting
Published Oct 30, 2026, 11:47 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 11:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ABBV
Bullish
high confidence
Mentioned
$ABBV
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ABBVBullishHigh
01

Why it matters

The beat on both EPS and revenue provides a fresh trading catalyst.

02

Market read

Earnings beat likely drives short-term price appreciation for ABBV and may influence sector sentiment.

03

What to watch

Potential headwinds from upcoming patent expirations not addressed in the release.

Relevance 9/10Novelty 9/10Timing: post-market today

Background

AbbVie’s Q3 earnings were released via a press release on Seeking Alpha.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

AbbVie reported Q3 Non-GAAP EPS of $3.82, beating expectations by $0.05 and revenue of $17.4B, beating by $50M.

Expected impact

likely upside as market prices in the earnings beat

Evidence & confidence

Both EPS and revenue exceeded consensus, providing a fresh catalyst for short-term buying pressure.

Market effects

Boosts outlook for the broader pharma sector as earnings beat may lift peers.

Positive impact on US healthcare indices.

Limited to US and global pharma investors.

Counterpoint

Some analysts may question sustainability of growth given higher guidance expectations.

Key entities

  • AbbVie

    US-listed biopharma company (ticker ABBV).

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$ABBVMed

AbbVie to Invest More than $200 Million in Puerto Rico to Modernize Barceloneta Manufacturing Campus

AbbVie (NYSE: ABBV) plans to invest $217 million to modernize its biologics manufacturing campus in Puerto Rico, creating 100 new jobs. The project, part of a $100 billion U.S. investment commitment, will integrate AI and advanced technologies to support current and future immunology and neuroscience medications. The facility is expected to be operational by 2030.